Latest news

• AZ expects return to growth this year after 2017 decline

  to $2.6bn, although the cumulative effect of patent expiries - which also affect antipsychotic Seroquel XR (quetiapine) and gastrointestinal drug Nexium (esomeprazole) - are starting to dissipate.

• AZ CEO says company’s renaissance is on track

  for cholesterol drug Crestor (rosuvastatin) and antipsychotic Seroquel XR (quetiapine).

• US appeals court upholds AstraZeneca’s Seroquel XR patent

  These include Teva, which launched its own versions of both Seroquel XR and Seroquel in the UK in March 2012. ... But it isn't just Seroquel XR that AZ is trying to prolong the life of.

• AZ's Q3 income up as sales stay flat

  The company said more than $350m of revenue was lost due to generic competition, cancelling out strong performances for statin Crestor (rosuvastatin calcium), antipsychotic Seroquel XR (quetiapine fumarate) and Symbicort

• AZ settles Seroquel patent case

  AstraZeneca has entered into a settlement agreement with Accord Health and Intas regarding patent litigation for Seroquel XR in the US. ... AstraZeneca (AZ) has entered into a settlement agreement with Accord Health and Intas regarding patent litigation